Nuevolution: Chemetics Proof Is In The Deal Making
Edison | Feb 16, 2017 08:54AM ET
Nuevolution's (ST:NUEVOL) proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. The technology has received powerful external validation, including two recent collaborations (Amgen (NASDAQ:AMGN) and Almirall (LON:0O9B)) that could generate significant value in the coming years. In addition, we expect Nuevolution to progress at least one internally generated asset into clinical development in the near future. We value the company's recent deals with Amgen and Almirall, plus its cash position alone, at SEK901m ($102m); our valuation does not include the technology, other pipeline assets and future deal opportunities.
Existing deals validate the technology
Chemetics, a DNA-encoded screening platform, is designed to rapidly select drugs for an array of tough-to-drug disease targets; the technology has been validated by multiple collaborative deals (17 since inception). Notably, deals with Amgen (multi-target: value up to $410m per target and a tiered royalty on sales) and Almirall (up to €442m plus tiered royalties for RORyt inverse agonist [dermatology and psoriatic arthritis indications] programme) are pivotal in defining near-term value.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.